ImmunityBio, Inc. IBRX Reportable Segment — Personnel-related costs
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by ImmunityBio, Inc. in its filing.
Tagged under the XBRL concept ibrx:ResearchAndDevelopmentExpenseInternalPersonnelRelatedCosts.
The official record: ImmunityBio, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about ImmunityBio, Inc.'s reportable segment — personnel-related costs.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is ImmunityBio, Inc.'s reportable segment — personnel-related costs?
- ImmunityBio, Inc. (IBRX) reported reportable segment — personnel-related costs of $25.85M in Q1 2026.
- How has ImmunityBio, Inc.'s reportable segment — personnel-related costs changed year-over-year?
- ImmunityBio, Inc.'s reportable segment — personnel-related costs increased by 12.1% year-over-year, from $23.07M to $25.85M.
- What is the long-term trend for ImmunityBio, Inc.'s reportable segment — personnel-related costs?
- Over 2 years (2023 to 2025), ImmunityBio, Inc.'s reportable segment — personnel-related costs has grown at a 3.1% compound annual growth rate (CAGR), from $89.09M to $94.77M.
- What does reportable segment — personnel-related costs mean?
- Includes all compensation-related expenses for employees dedicated to the segment, such as salaries, bonuses, benefits, and stock-based compensation. It reflects the human capital investment required to operate the segment.